蛋白质组分析确定了瘤性KRAS信号传递的目标,途径和细胞后果
Nicole Kabella1, Florian P Bayer1, Konstantinos Stamatiou2
1School of Life Sciences, Technical University of Munich, Freising, Germany.
Science signaling
|July 29, 2025
概括
用药物向KRAS突变,通过诱导细胞周期退出来阻止癌细胞生长. 蛋白质组分析显示,在这种静止状态期间,蛋白质的修饰发生了广泛的变化,而不是重塑.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症基因组学 癌症基因组学
背景情况:
- 小型GTPase KRAS中的激活突变是许多癌症的常见驱动因素.
- 药物发现已经产生了向KRAS活动及其下游信号通路的抑制剂.
- 了解这些抑制剂的精确作用对于有效的癌症治疗至关重要.
研究的目的:
- 为了研究针对性抑制剂的反应中的瘤性KRAS信号.
- 阐明KRAS向药物的细胞静止作用和分子机制.
- 为了确定蛋白质丰度的变化和对治疗的反应后的翻译后修改.
主要方法:
- 在人类KRAS突变胰腺癌和肺癌细胞系上进行了蛋白质组分析,包括光蛋白质组分析.
- 细胞接受了针对KRAS,MEK,ERK,SHP2和SOS1.1的抑制剂的治疗.
- 为了分析时间动态,在短期和长期药物暴露后进行了蛋白质组的比较.
主要成果:
- 确定了一个核心的KRAS信号签名和特定于细胞线的网络.
- 自主性,瘤性KRAS活性在细胞系中主导着蛋白质组.
- 抑制KRAS-MEK-ERK轴导致细胞周期退出,其特征是广泛的酸化和无处不在的变化,没有显著的蛋白质组重塑.
结论:
- 针对KRAS的疗法诱导细胞周期退出,这是避免细胞死亡的机制.
- 蛋白质组的洞察力揭示了途径抑制的时间动态及其对细胞状态的影响.
- 该研究确定了参与瘤性KRAS信号传递及其抑制的其他蛋白质.
更多相关视频
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
8.0K
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
11.3K
相关概念视频
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
The Ras Gene
6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.4K
MAPK Signaling Cascades
6.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.1K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
Small GTPases - Ras and Rho
4.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.2K
Interactions Between Signaling Pathways
6.5K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.5K
